

Product Center
Marketing application for quadrivalent influenza virus subunit vaccine for children aged 6-35 months accepted!
- Categories:Company news
- Author:
- Origin:
- Time of issue:2024-06-28
- Views:
(Summary description)On June 28, 2024, Ab&B Bio Tech Co., Ltd. (hereinafter referred to as "Ab&B Bio") applied for the launch of the "quadrivalent influenza virus subunit vaccine" and was accepted by the Drug Evaluation Center (CDE) of the State Medical Products Administration of China.
Marketing application for quadrivalent influenza virus subunit vaccine for children aged 6-35 months accepted!
(Summary description)On June 28, 2024, Ab&B Bio Tech Co., Ltd. (hereinafter referred to as "Ab&B Bio") applied for the launch of the "quadrivalent influenza virus subunit vaccine" and was accepted by the Drug Evaluation Center (CDE) of the State Medical Products Administration of China.
- Categories:Company news
- Author:
- Origin:
- Time of issue:2024-06-28 10:17
- Views:
On June 28, 2024, Ab&B Bio Tech Co., Ltd. (hereinafter referred to as "Ab&B Bio") applied for the launch of the "quadrivalent influenza virus subunit vaccine" and was accepted by the Drug Evaluation Center (CDE) of the State Medical Products Administration of China.

Source: Drug Evaluation Center of the National Medical Products Administration
At present, influenza virus remains one of the important respiratory pathogens threatening human public health. Seasonal influenza outbreaks or occasional cross species transmission and pandemics of influenza virus have significant impacts on human health and socio-economic development. Especially for infants, the elderly, and patients with underlying cardiovascular and pulmonary diseases, infection with influenza virus may lead to serious complications such as pneumonia, resulting in severe illness or death. At present, getting vaccinated against influenza is the most effective measure to prevent influenza diseases and pandemics.
The acceptance of the application for the launch of the quadrivalent influenza virus subunit vaccine for children aged 6-35 months is another significant development for Ab&B Bio subunit influenza vaccine family. The vaccine has completed phase three clinical trials and reached the expected endpoint of the clinical trials. This high-quality vaccine, which combines high purity, low side effects, good safety, and comprehensive protection, will become China's first universal quadrivalent influenza virus subunit vaccine for the entire population! Expected to be approved for listing in 2025! Ab&B Bio will continue to work hard and achieve the launch of multiple products as soon as possible, safeguarding human life and health!
Relevant information
-
Ab&B Bio and Yither Bio have both obtained qualification certification!
Recently, Ab&B Bio-Tech Co.,Ltd(Ab&B Bio) and its subsidiary Yither biotech (Shanghai) Co., Ltd (Yither Bio) have been recognized as Jiangsu Province's specialized and innovative small and medium-sized enterprises and national high-tech enterprises, respectively. - The kickoff meeting for clinical research on the immunogenicity and safety of quadrivalent influenza virus subunit vaccine for children with nephrotic syndrome was successfully held 12-25
- Influenza virus subunit vaccine (adjuvant) IND application approved 10-30
- The application for the marketing of trivalent influenza virus subunit vaccine has been accepted! 10-08
- Breaking through bottleneck technology, significant progress has been made in the research and development of new adjuvants 08-26
Have a project?Get a touch!
Caring for life, protecting health, and making global technological innovation vaccines are the mission of Ab&B Bio
Contact
E-mail:info@abbbio.com.cn
Add:No. 32, Xinglin Road, Medical High-tech Zone, Taizhou City
Quick view
Follow us